Associations of HLA‐C*01:02 and HLA‐B*46:01 with regorafenib‐induced erythema multiforme in Japanese patients with metastatic colorectal cancer

Regorafenib improves the survival of patients with metastatic colorectal cancer (mCRC); however, it is also characterized by detrimental dermal side effects that may require treatment cessation or modified dosing. In our previous prospective pharmacokinetic, pharmacodynamic, and pharmacogenetic stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Ken‐ichi, Matsumoto, Natsumi, Murase, Remi, Takeshima, Kosuke, Ishida, Hiroo, Kubota, Yutaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582655/
https://www.ncbi.nlm.nih.gov/pubmed/37424405
http://dx.doi.org/10.1111/cts.13589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582655/
https://www.ncbi.nlm.nih.gov/pubmed/37424405
http://dx.doi.org/10.1111/cts.13589

Ejemplares similares